access to a novel and acceptable treatment.
elimination of ineffective treatments.
decreasing drug-induced complications.
comparison of effect of Atazanavir/Ritanavir and Lopinavir/Ritanavir on inflammatory biomarkers including ESR and CRP.
comparison of effect of Atazanavir/Ritanavir and Lopinavir/Ritanavir on respiratory involvement including Pneumonia and COViD-19 induced ARDS
comparison of effect of Atazanavir/Ritanavir and Lopinavir/Ritanavir on hospitalization duration.
comparison of effect of Atazanavir/Ritanavir and Lopinavir/Ritanavir on drug-induced GI complications.
comparison of effect of Atazanavir/Ritanavir and Lopinavir/Ritanavir on mortality/morbidity rate decrease.
This clinical trial is a double-blinded case-control randomized study on 100 patients. Permuted block randomization technique was used for patients randomization.
Settings and conduct
This study will be performed in Bahonar hospital at the first 6 months of the year. Statistical analyses will be accomplished using STATA software.
This study is designed double-blinded (patients and physicians). Patients of each group (case or control) will be hospitalized in a specific place and do not have any contact with patients of the opposite group.
Participants/Inclusion and exclusion criteria
Patients between 20-80 years admmited to the hospital whose diseases were confirmed by CT, RT-PCR.
Atazanavir/Ritonavir treatment group receives novel treatment and Lopinavir/Ritonavir treatment group receives standard treatment. adverse effects and desired effects will be assessed.
Main outcome variables
Clinic and Para clinic findings in COViD-19 patients.
Mortality and morbidity rate in COViD-19 patinets.
Duration of hospitalization.
Reason for update
IRCT registration information
IRCT registration number:IRCT20200504047298N1
Registration date:2020-06-14, 1399/03/25
Last update:2020-06-14, 1399/03/25
Name of organization / entity
Iran (Islamic Republic of)
+98 21 4602 2136
Expected recruitment start date
Expected recruitment end date
Actual recruitment start date
Actual recruitment end date
Trial completion date
Evaluation of Atazanavir/Ritonavir effect on COViD-19 patients treatment in comparison with Lopinavir / Ritonavir
Effect of Atazanavir/Ritonavirin treatment of COViD-19
Patients randomized classification into standard treatment group and case group was performed using permuted block randomization. in this study, four-unit blocks were used. Using R software, a chain of randomized numbers comprising one to six are created to reach the desired sample size.
Blinding (investigator's opinion)
In this study, patients, researchers, and health workers were blind.
This study is designed double-blinded. Patients of each group (case or control) will be hospitalized in a specific place and do not have any contact with patients of the opposite group. Besides, a member of the research team and a doctor of infectious diseases will prescribe according to assigned treatment codes.
Other design features
Name of ethics committee
Ethics committee of Alborz University Of Medical Sciences
Research Department, Safarian Alley, Golshahr Avenue
Ethics committee reference number
Health conditions studied
Description of health condition studied
ICD-10 code description
Use this code when COVID-19 has been confirmed by laboratory testing irrespective of severity of clinical signs or symptoms. Use additional code, if desired, to identify pneumonia or other manifestations.
COViD-19 patients clinical progression
frequently in hospitalization time
Method of measurement
need to be intubated, body temperature, heart rate, respiratory rate, cough, dyspnea, ICU admission.